RxDoctor Payments DataLook up a doctor →

Kishor Vora, MD

Cardiovascular Disease · Owensboro, KYNPI 1992753727

Payments from drug & device makers

$4,488,663in general payments, 2019–2025

Across 926 payments — averaging $4847.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1M
  • AstraZeneca$840K
  • Astrazeneca UK Limited$642K
  • Novartis$596K
  • Romark Laboratories, LC$557K
  • AbbVie$338K
  • plus $482K from 47 others

What the payments were for

  • Consulting fees$1,6008%
  • Speaking & faculty fees$10,60050%
  • Travel & lodging$3,97319%
  • Food & beverage$4,86323%
  • Education$1971%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,488,663 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,607,797
Medicare patients
1,854
Services billed
71,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban924$877,566
EntrestoSacubitril/Valsartan682$842,228
FarxigaDapagliflozin Propanediol410$401,747
XareltoRivaroxaban177$164,402
Repatha SureclickEvolocumab127$103,135
JardianceEmpagliflozin69$69,510
Ranolazine ErRanolazine729$63,453
BrilintaTicagrelor78$61,150
Potassium Chloride1,327$24,575
ClopidogrelClopidogrel Bisulfate2,649$24,027
Praluent PenAlirocumab32$18,752
Isosorbide Mononitrate ErIsosorbide Mononitrate1,911$18,734
Atorvastatin Calcium1,685$13,316
Prasugrel Hcl114$12,123
Metoprolol Succinate1,125$11,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$877,566924 claims
NovartisEntresto$596,490$842,228682 claims
AstraZenecaFarxiga, Brilinta$839,606$462,898488 claims
Johnson & JohnsonXarelto$235$164,402177 claims
Boehringer IngelheimJardiance$1,033,459$69,51069 claims
Lexicon Pharmaceuticals, Inc.Inpefa$125$9,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →